These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 22045497)
21. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805 [TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262 [TBL] [Abstract][Full Text] [Related]
23. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648 [TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336 [TBL] [Abstract][Full Text] [Related]
25. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777 [TBL] [Abstract][Full Text] [Related]
26. A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. Llano DA; Bundela S; Mudar RA; Devanarayan V; PLoS One; 2017; 12(8):e0182098. PubMed ID: 28771542 [TBL] [Abstract][Full Text] [Related]
27. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467 [TBL] [Abstract][Full Text] [Related]
28. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867 [TBL] [Abstract][Full Text] [Related]
29. Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. van Steenoven I; Koel-Simmelink MJA; Vergouw LJM; Tijms BM; Piersma SR; Pham TV; Bridel C; Ferri GL; Cocco C; Noli B; Worley PF; Xiao MF; Xu D; Oeckl P; Otto M; van der Flier WM; de Jong FJ; Jimenez CR; Lemstra AW; Teunissen CE Mol Neurodegener; 2020 Jun; 15(1):36. PubMed ID: 32552841 [TBL] [Abstract][Full Text] [Related]
30. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
32. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966 [TBL] [Abstract][Full Text] [Related]
33. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282 [TBL] [Abstract][Full Text] [Related]
34. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. Monge-Argilés JA; Sánchez-Payá J; Muñoz-Ruiz C; Pampliega-Pérez A; Gómez-López MJ; Rodríguez Borja E; Montoya-Gutiérrez J; Leiva-Santana C Neurologia; 2012 Jan; 27(1):28-33. PubMed ID: 21621878 [TBL] [Abstract][Full Text] [Related]